Published in J Clin Invest on February 01, 2011
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature (2013) 3.55
Corticostriatal connectivity and its role in disease. Nat Rev Neurosci (2013) 2.34
Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol (2012) 1.32
Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci (2013) 1.31
Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage (2011) 1.15
The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest (2011) 1.11
The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol Neurodegener (2013) 1.01
Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease. Neuroimage (2011) 0.98
Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci Lett (2012) 0.97
Metabolic network as a progression biomarker of premanifest Huntington's disease. J Clin Invest (2013) 0.95
The protective and therapeutic function of small heat shock proteins in neurological diseases. Front Immunol (2012) 0.94
Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem (2012) 0.93
Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. J Neurosci (2016) 0.92
Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord (2012) 0.89
Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits. J Neurosci (2014) 0.87
Toward sophisticated basal ganglia neuromodulation: Review on basal ganglia deep brain stimulation. Neurosci Biobehav Rev (2015) 0.85
Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains. Hum Mol Genet (2014) 0.85
Synaptic dysfunction and septin protein family members in neurodegenerative diseases. Mol Neurodegener (2015) 0.82
Current status of PET imaging in Huntington's disease. Eur J Nucl Med Mol Imaging (2016) 0.78
Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol Dis (2014) 0.78
Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's disease. Funct Neurol (2015) 0.75
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature (2010) 7.35
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell (2004) 5.67
Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science (2010) 5.48
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology (2002) 5.40
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science (1995) 5.19
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci (2007) 4.93
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev (2010) 3.69
The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J Neurosci (1996) 3.20
Synaptic organisation of the basal ganglia. J Anat (2000) 3.12
BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem (2007) 2.96
Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol (2009) 2.93
Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci (1996) 2.89
Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A (1988) 2.78
Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci (2002) 2.75
Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology (2003) 2.73
The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron (2005) 2.68
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med (2009) 2.66
Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol (1997) 2.64
Homeostatic signaling: the positive side of negative feedback. Curr Opin Neurobiol (2007) 2.58
Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron (2010) 2.36
The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci (2004) 2.33
Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci (2008) 2.29
The integrative function of the basal ganglia in instrumental conditioning. Behav Brain Res (2008) 2.19
Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci (2008) 2.16
Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci (2009) 2.16
Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci (2004) 2.16
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.15
Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology (2010) 2.14
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
Brain structure in preclinical Huntington's disease. Biol Psychiatry (2005) 2.05
Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med (1990) 1.89
Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology (2006) 1.88
Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems. J Biol Chem (2007) 1.84
Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol (1997) 1.82
Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci (2004) 1.76
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem (2005) 1.68
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem (2007) 1.64
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain (1996) 1.64
Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol (1999) 1.63
Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci (2010) 1.62
The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience (2000) 1.55
Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain (2007) 1.54
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol (1997) 1.53
Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci (2010) 1.50
Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol (2000) 1.47
Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci (2007) 1.45
Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain (1990) 1.44
Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci (2007) 1.44
Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. Neuroimage (2010) 1.43
Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener (2007) 1.39
Preclinical Huntington's disease: compensatory brain responses during learning. Ann Neurol (2006) 1.36
Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res (2005) 1.35
Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci (2006) 1.35
Functional brain changes in presymptomatic Huntington's disease. Ann Neurol (2004) 1.34
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord (2005) 1.33
Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology (2001) 1.33
HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. Nat Neurosci (2010) 1.32
Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol (2007) 1.32
Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex (2004) 1.32
Cortical and thalamic innervation of direct and indirect pathway medium-sized spiny neurons in mouse striatum. J Neurosci (2010) 1.32
Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology (1991) 1.30
Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet (1999) 1.29
Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull (2006) 1.28
Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci (2008) 1.26
Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med (2001) 1.25
Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci (2006) 1.25
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009) 1.18
Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci (1999) 1.18
Reciprocal Benefits of Mass-Univariate and Multivariate Modeling in Brain Mapping: Applications to Event-Related Functional MRI, H(2) (15)O-, and FDG-PET. Int J Biomed Imaging (2006) 1.16
Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease. Neurology (1992) 1.14
Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. J Neurosci (1999) 1.13
Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem (2004) 1.10
Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci (2001) 1.10
Presynaptic BDNF promotes postsynaptic long-term potentiation in the dorsal striatum. J Neurosci (2010) 1.08
Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain (2010) 1.08
Functional imaging in Huntington's disease. Exp Neurol (2009) 1.08
Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem (2005) 1.04
The role of dopamine in modulating the structure and function of striatal circuits. Prog Brain Res (2010) 1.04
Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience (2007) 1.03
Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro (2010) 1.03
Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience (2000) 1.02
Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience (1995) 1.00
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother (2010) 1.00
Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. Exp Brain Res (2005) 1.00
[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol (1998) 0.99
Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J (2006) 0.99
Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol (2010) 0.96
Pallidal neuronal discharge in Huntington's disease: support for selective loss of striatal cells originating the indirect pathway. Exp Neurol (2008) 0.96
Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx (2004) 0.96
Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology (2005) 0.95
Therapeutic options for Huntington's disease. Curr Opin Investig Drugs (2003) 0.94
Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis (2005) 0.94
Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci (2008) 0.93
Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener (2010) 0.93
A translational profiling approach for the molecular characterization of CNS cell types. Cell (2008) 8.69
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Dichotomous dopaminergic control of striatal synaptic plasticity. Science (2008) 5.47
'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature (2007) 5.03
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
Modulation of striatal projection systems by dopamine. Annu Rev Neurosci (2011) 4.84
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature (2010) 4.07
Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron (2006) 3.58
Kalirin-7 controls activity-dependent structural and functional plasticity of dendritic spines. Neuron (2007) 2.93
Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron (2010) 2.92
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A (2010) 2.36
Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci (2009) 2.35
Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci (2008) 2.29
Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron (2009) 2.26
Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci (2007) 2.19
Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci (2007) 2.15
Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci (2008) 2.10
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science (2013) 1.95
Corticostriatal and thalamostriatal synapses have distinctive properties. J Neurosci (2008) 1.86
G-protein-coupled receptor modulation of striatal CaV1.3 L-type Ca2+ channels is dependent on a Shank-binding domain. J Neurosci (2005) 1.84
Differential excitability and modulation of striatal medium spiny neuron dendrites. J Neurosci (2008) 1.79
Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci (2012) 1.70
Dendritic excitability of mouse frontal cortex pyramidal neurons is shaped by the interaction among HCN, Kir2, and Kleak channels. J Neurosci (2005) 1.67
Alternatively spliced isoforms of TRIP8b differentially control h channel trafficking and function. J Neurosci (2009) 1.63
Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci (2005) 1.61
RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci (2006) 1.58
Transmitter modulation of slow, activity-dependent alterations in sodium channel availability endows neurons with a novel form of cellular plasticity. Neuron (2003) 1.51
Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. Proc Natl Acad Sci U S A (2009) 1.49
Corticospinal-specific HCN expression in mouse motor cortex: I(h)-dependent synaptic integration as a candidate microcircuit mechanism involved in motor control. J Neurophysiol (2011) 1.48
HCN2 and HCN1 channels govern the regularity of autonomous pacemaking and synaptic resetting in globus pallidus neurons. J Neurosci (2004) 1.47
D2 dopamine receptor-mediated modulation of voltage-dependent Na+ channels reduces autonomous activity in striatal cholinergic interneurons. J Neurosci (2004) 1.39
Neuromodulation of Na+ channel slow inactivation via cAMP-dependent protein kinase and protein kinase C. Neuron (2006) 1.38
Regulation of intrinsic excitability in hippocampal neurons by activity-dependent modulation of the KV2.1 potassium channel. Channels (Austin) (2009) 1.38
FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat Neurosci (2008) 1.36
Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci (2009) 1.34
HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. Nat Neurosci (2010) 1.32
Nav1.6 sodium channels are critical to pacemaking and fast spiking in globus pallidus neurons. J Neurosci (2007) 1.31
Kv1.2-containing K+ channels regulate subthreshold excitability of striatal medium spiny neurons. J Neurophysiol (2003) 1.31
MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. Mol Cell Neurosci (2010) 1.30
A mechanism for homeostatic plasticity. Nat Neurosci (2004) 1.26
RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. Proc Natl Acad Sci U S A (2004) 1.26
Kv3.4 subunits enhance the repolarizing efficiency of Kv3.1 channels in fast-spiking neurons. Nat Neurosci (2003) 1.25
Association of CaV1.3 L-type calcium channels with Shank. J Neurosci (2005) 1.25
Sodium currents in medullary neurons isolated from the pre-Bötzinger complex region. J Neurosci (2005) 1.24
Enhancement of excitatory synaptic integration by GABAergic inhibition in the subthalamic nucleus. J Neurosci (2005) 1.24
CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun (2012) 1.20
Calcium-activated SK channels influence voltage-gated ion channels to determine the precision of firing in globus pallidus neurons. J Neurosci (2009) 1.17
Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. J Neurosci (2002) 1.17
Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord (2008) 1.16
Modulation of striatal single units by expected reward: a spiny neuron model displaying dopamine-induced bistability. J Neurophysiol (2003) 1.15
Ca1.2 and CaV1.3 neuronal L-type calcium channels: differential targeting and signaling to pCREB. Eur J Neurosci (2006) 1.15
Coupling of L-type Ca2+ channels to KV7/KCNQ channels creates a novel, activity-dependent, homeostatic intrinsic plasticity. J Neurophysiol (2008) 1.15
Synaptically driven state transitions in distal dendrites of striatal spiny neurons. Nat Neurosci (2011) 1.13
Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord (2012) 1.11
Muscarinic modulation of striatal function and circuitry. Handb Exp Pharmacol (2012) 1.11
Neuroscience: To go or not to go. Nature (2013) 1.11
Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci (2013) 1.10
M1 muscarinic receptor modulation of Kir2 channels enhances temporal summation of excitatory synaptic potentials in prefrontal cortex pyramidal neurons. J Neurophysiol (2007) 1.10
Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology (2007) 1.09
Convergent cortical innervation of striatal projection neurons. Nat Neurosci (2013) 1.08
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2008) 1.07
Strain-specific regulation of striatal phenotype in Drd2-eGFP BAC transgenic mice. J Neurosci (2012) 1.07
Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade. J Neurophysiol (2002) 1.06
Thalamic contributions to Basal Ganglia-related behavioral switching and reinforcement. J Neurosci (2011) 1.04
Proliferation of external globus pallidus-subthalamic nucleus synapses following degeneration of midbrain dopamine neurons. J Neurosci (2012) 1.01
Selective participation of somatodendritic HCN channels in inhibitory but not excitatory synaptic integration in neurons of the subthalamic nucleus. J Neurosci (2010) 0.98
Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord (2013) 0.98
A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov Disord (2010) 0.95
Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease. Behav Brain Res (2011) 0.93
Striatal information signaling and integration in globus pallidus: timing matters. Neurosignals (2005) 0.91
Regulation of dendritic calcium release in striatal spiny projection neurons. J Neurophysiol (2013) 0.89
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem (2010) 0.87
Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord (2010) 0.86
Do substantia nigra dopaminergic neurons differentiate between reward and punishment? J Mol Cell Biol (2009) 0.84
Structure-activity relationship of N,N'-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson's disease. J Med Chem (2013) 0.84
Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion. Neurobiol Dis (2011) 0.83
Astrocytes go awry in Huntington's disease. Nat Neurosci (2014) 0.78
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron (2016) 0.76
Spectral reconstruction of phase response curves reveals the synchronization properties of mouse globus pallidus neurons. J Neurophysiol (2013) 0.75
Corrigendum: Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature (2015) 0.75
Multiphoton imaging approaches for studying striatal dendritic excitability. Methods Mol Biol (2014) 0.75